Eli Lilly, a US-based pharma company is all set to launch a new medication to enhance its diabetes treatment portfolio by the end of the year in India.
The company has received regulatory approval for the upcoming product. It is also gearing up to introduce another medication in oncology that could be launched by the end of 2016 or by early 2017.
In an interview to a news agency, Managing Director Edgard A Olaizola said that they are planning to introduce a new medication later this year in diabetes and also received the approvals for the same. He also added that the diabetes is their primary segment with around 60 to 70 per cent of revenues in India from diabetes followed by oncology and osteoporosis.
The company considers the US, Europe as a region and Japan as the biggest market globally and India is an important market in Asia.